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Background and Aim. ROHHADNET (rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation,
neuroendocrine tumor) syndrome is a rare disease with grave outcome. Although early recognition is essential, prompt diagnosis
may be challenging due to its extreme rarity. This study aimed to systematically review its clinical manifestation and to identify
genetic causes. Materials and Methods. We firstly conducted a systematic review on ROHHAD/NET. Electronic databases were
searched using related terms. We secondly performed whole exome sequencing (WES) and examined copy number variation
(CNV) in two patients to identify genetic causes. Results. In total, 46 eligible studies including 158 patients were included. There
were 36 case reports available for individual patient data (IPD; 48 patients, 23 ROHHAD, and 25 ROHHADNET) and 10 case
series available for aggregate patient data (APD; 110 patients, 71 ROHHAD, and 39 ROHHADNET). The median age at onset
calculated from IPD was 4 years. Gender information was available in 100 patients (40 from IPD and 60 from APD) in which
65 females and 35 males were showing female preponderance. Earliest manifestation was rapid obesity, followed by hypothalamic
symptoms. Most common types of neuroendocrine tumors were ganglioneuromas. Patients frequently had dysnatremia and
hyperprolactinemia. Two patients were available for WES. Rare variants were identified in PIK3R3, SPTBN5, and PCF11 in one
patient and SRMS, ZNF83, and KMT2B in another patient, respectively. However, there was no surviving variant shared by
the two patients after filtering. Conclusions. This study systematically reviewed the phenotype of ROHHAD/NET aiming to
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1. Introduction
Rapid-onset obesity with hypoventilation, hypothalamic,
autonomic dysregulation (ROHHAD) syndrome is a rare dis-
order of respiratory failure and autonomic dysregulation with
endocrine abnormalities [1]. The suffix -NET was later added
to describe a subset of patients with ROHHAD who were
foundwith neuroendocrine tumors (NET) as ROHHADNET
[2].
ROHHAD or ROHHADNETmay mimic genetic obesity
syndromes and present with hypothalamic-pituitary dys-
functions which are not fully investigated [3]. Since the
central respiratory control becomes progressively impaired in
the patients, the outcome is often fatal and associated with
cardiopulmonary arrest [4]. Prompt diagnosis based on early
recognition is essential to provide timely respiratory sup-
port and to minimize morbidity and mortality. We thereby
sought to systematically review the clinical manifestation,
laboratory profiles, and treatment strategies of patients with
ROHHAD/NET to help understanding and managing the
disease. In addition, we performed whole exome sequencing
(WES) in 2 patients with ROHHADNET in the attempt to
identify the genetic causes.
2. Methods
2.1. Search Methods. We conducted a systematic review of
the medical literature to identify all published cases of
ROHHAD and/or -NET using the online databases of MED-
LINE/PubMed, EMBASE, and Google Scholar, until July
7th, 2018. There were no language restrictions; non-English
language articles were translated and included. The broad
search query was designed to include “ROHHADNET” OR
“ROHHAD”; OR “obesity” AND two of the following terms;
“hypoventilation” OR “hypothalamic” OR “autonomic” OR
“tumor” OR “neural crest tumor” OR “neuroendocrine
tumor.” We reviewed the titles, abstracts, and full texts
adhering to the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) individual patient
data (IPD) guidelines (Figure 1; Supplementary Table S1) [5].
2.2. Eligibility Criteria. The basic criteria for consideration
of the diagnosis of ROHHAD had been published by Ize-
Ludlow et al. [6]. The criteria briefly included the following:
(1) onset of rapid and extreme weight gain after an age of 1.5
years (typically 2–7 years) in a previously nonobese and seem-
ingly normal child, (2) evidence of hypothalamic dysfunc-
tion, (3) alveolar hypoventilation, and (4) features of auto-
nomic dysregulation.We collected published case reports and
case series which contained data on clinical manifestations
fulfilling the criteria of ROHHAD/NET. Due to the extreme
paucity of data, congress abstracts were also included. All
cases from the literature were included as applicable.
2.3. Exclusion Criteria. Duplicates, letters, commentaries, or
replies were excluded. Original articles not containing patient
data, such a review articles, were also excluded.
2.4. Selection of Studies. Two reviewers (J.M.L, and S.K.)
working independently considered the potential eligibility of
each abstract and title that resulted from the initial search.
The full-text versions of the eligible studies were reviewed.
Disagreements were harmonized by consensus and, if not
possible, through arbitration by a third reviewer (J.I.S.).
2.5. Data Extraction. Data were extracted from all of the case
reports and case series which were included in the system-
atic review. Demographic information included age, gender,
and ethnicity. Clinical manifestation included presence of
symptoms, such as hypothalamic dysfunction, hypoventi-
lation, autonomic dysregulation, neuroendocrine tumors,
and neurologic or other remarkable reports. Data regarding
the laboratory findings, management strategy, and clinical
outcomes were also examined.
2.6. DNA Preparation, Whole Exome Sequencing, Sequence
Alignment, and Variant Calling. This study was approved
by the institutional review board of the Severance Hospital,
Yonsei University Health System (IRB No.2017-2991-001).
There were two patients with ROHHADNET with available
samples, Case 1 [7] and Case 2 [8] (Supplementary Table
S2). After obtaining informed consent, whole blood (3 ml)
was collected from the two individuals with ROHHADNET.
Genomic DNA was extracted using RBC Lysis Solution, Cell
Lysis Solution, and Protein Precipitation Solution (iNtRon
Biotechnology, Inc). Whole exome capture was performed
using the Agilent SureSelect V5 enrichment capture kit (Agi-
lent Technologies). The enriched library was then sequenced
using the HiSeq 2500 sequencing system (Illumina; 101-base
paired-end sequencing). Image analysis and base calling were
performedwith the Pipeline software (Illumina) using default
parameters. Sequence reads were mapped to the human
reference genome assembly (GRCh37/hg19) using the CLC
Genomic Workbench (version 9.0.1) software (QIAGEN).
Mapping was performed using the “Map Reads to Reference”
function of the CLC Genomic Workbench software with the
following settings:mismatch cost, 2; insertion cost, 3; deletion
cost, 3; length fraction, 0.5; similarity fraction, 0.9; and
map to nonspecific reads, random. Nonspecific reads were
ignored for count and coverage. All variants with aminimum
coverage of 2 were called using the “Basic Variant Caller”
function of the CLC Genomic Workbench and annotated.
2.7. Filtering and Evaluation of Variants. Whole exome
sequencing was analyzed as previously described [9]. Briefly,
variants with minor allele frequencies >1% in the single
nucleotide polymorphism (dbSNP; version 138) or 1000
genomes (2504 individuals; phase 3 data) databases were
excluded. In the second step, variants present in the homozy-
gous or hemizygous state in 59 healthy individuals with-
out ROHHAD syndrome (internal control WES data) were
excluded. In step 3, synonymous variants and intronic vari-
ants not located within splice site regions were excluded.
In step 4, a recessive inheritance pattern was assumed on
the basis of the pedigree of affected individuals. Therefore,
homozygous and biallelic compound heterozygous vari-
ants were retained, while single heterozygous variants were
excluded from further evaluation. In Case 1 who was a
male, hemizygous variants were also considered. De novo
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variants could not be evaluated because parental DNAs were
not available. In the final step, the remaining variants were
ranked based on conservation of the mutated amino acid
residue across species and their probable impact on the
function of the encoded protein.The remaining variants were
confirmed in the original participant DNA samples by Sanger
sequencing.
2.8. Copy Number Variant (CNV) Analysis. Analysis of CNV
was performed using the paired-end WES data using the
EXCAVATOR version 2.2 [10] and ExomeDepth version 1.1.10
tools [11] with default settings. The GRCh37/hg19 database
was used as the reference assembly for calculation of GC
content. The WES dataset of 11 internal control subjects was
compared with that of the study participants. Copy number
variations at specific target regions were estimated according
to different CNV detection algorithms using the Agilent
SureSelect V5 kit.
3. Results
In total, 321 articles were identified using electronic and
manual search methods (Figure 1). After serially reviewing
the titles, abstracts, and full texts, 46 eligible studies including
158 patients were included. Among them, there were 36 case
reports available for individual patient data (IPD; 48 patients,
23 ROHHAD and 25 ROHHADNET) [3, 4, 7, 8, 12–43]. The
remaining ten studies were reporting patients in groups or
cohorts and were therefore available for aggregate patient
data (APD; 110 patients, 71 ROHHADand 39ROHHADNET)
[6, 44–50].
Data regarding gender were available in 100 patients
(40 from IPD and 60 from APD). There were 65 females
and 35 males showing female preponderance, and female to
male ratio was 1.9 to 1. Aside from gender, most of clinical
information was extracted from 36 case reports where IPD
were available. Limited information was retrievable from
10 studies with APD. Detailed profiles of the studies and
patients’ data are presented in Tables 1 and 2.
3.1. Individual Patient Data (IPD) from Case Reports. There
were 48 patients in the 36 case reports, in which 100% were
pediatric cases. The median age at the time of diagnosis was
4.0 years (range, 1-15). Twelve patients (12/40, 30 %) were
boys, 28 (28/40, 70%) were girls, and no information could
be retrieved in the 8 remainders. Female to male ratio from
IPD was 2.3 to 1.
3.1.1. Clinical Presentation. The most common presentation
of patients with ROHHAD/NET was rapid obesity and
hypothalamic dysfunction found in 40 cases (83%) respec-
tively, followed by hypoventilation reported in 36 cases
(75%).Hypothalamic dysfunction presented in various forms
of endocrine disorder, such as growth hormone deficiency
(25%), diabetes insipidus (19%), and central precocious
puberty (15%). Hypoventilation most commonly presented
as obstructive sleep apnea (44%). For symptoms of auto-
nomic dysregulation, ophthalmologic abnormality such as
blurred vision was most commonly reported (25%), fol-
lowed by altered pain perception (13%) and gastrointestinal
dysmotility (13%). Excessive sweating was noted in 10%
of the patients. Behavioral change was a common (60%)
form of cognitive dysfunction, and the symptoms included
mood changes, fatigue, social withdrawal, poor school per-
formance, and intellectual disability. Other neurologic man-
ifestations majorly included seizures, altered consciousness,
sleep disturbance, and developmental delay. The clinical
presentations of the patients are summarized in Table 3.
3.1.2. Laboratory Findings. In 13 patients who had available
datasets, all had hypoxemia at initial presentation and hyper-
capnia was also dominant (14/15, 93%; Table 4). Dysnatremia
was accompanied in most of the patients (30/31, 97%):
25 hypernatremia and 5 hyponatremias. Hyperprolactine-
mia (27/28, 96%), decreased IGF-1 level (12/16, 75%), and
hypothyroidism (18/30, 60%) were also common.
3.1.3. Treatment Strategies and Survival. At the time of
diagnosis, high proportion of patients (21/48, 44%) required
respiratory support: mechanical ventilation in 20 (42%) cases
and tracheostomy in 6 (13%) cases (Table 5). Six of the
44 (14%) patients were treated with steroids, while other
immunosuppressive measures including rituximab and/or
cyclophosphamide were administered in 7 cases (7/48, 14%).
There were 4 deaths (3 sudden cardiac arrests and 1 multior-
gan failure after sepsis) out of the 48 cases (Table 1).
3.1.4. Tumor Presentation. Out of 48 patients, twenty-five
had neuroendocrine tumors (52.1%). The features of the
tumors are described in Table 6. The most common type was
ganglioneuromas: 15 ganglioneuromas (60%), 9 ganglioneu-
roblastomas (36%), and 1 hamartomawith neural tissue (2%).
Although the lesions usually presented as intra-abdominal
mass, 2 cases with mediastinal masses were reported.
3.2. Aggregate Patient Data (APD). The 10 studies with APD
included 110 patients (Figure 1; Table 2). Although limited
data were available regarding age, all of the reported were
pediatric cases. Sixty patients were available for gender
information: 23 males (38%) and 37 females (62%). Female
predilection was consistently noted. Rapid-onset obesity was
observed in 65% (71/110) of the patients. Hypoventilation
was reported in 51/110 (46%) patients, 63% of them (32/51)
presented with sleep apnea, supporting the findings from
IPD. Autonomic dysfunction was reported in 80/106 (75%)
patients and behavioral changes were observed in 40/110
(36%). There were 46/110 (42%) patients who had neuroen-
docrine tumors and ganglioneuroma was the most common
type as in IPD (12/46; the remaining 34 were not available for
histology). In line with the IPD results, dysnatremia was the
most commonly observed electrolyte imbalance (21/27, 78%).
Information regarding treatment strategies was available in
51 patients and 100% of them eventually received artificial
ventilation. There were 12 deaths (9 sudden cardiac arrests
and 2 not available for cause of death) out of the 110 patients.
The frequencies and characteristics of clinical manifestation
generally conformed to those from IPD.
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N° studies screened for eligibility (321)
N° studies excluded (275)
not about ROHHAD/NET (238)
reviews (21)
no patient data (6)
duplicates (6)
commentaries/replies/letters (4)
N° studies for which IPD were sought (46)
N° eligible studies for which IPD were not sought (0)
N° studies for which IPD were provided (36)
N° participants for whom data were provided (48)
N° participants for whom no data were provided (0)
N° studies for which IPD were not provided (10) (data 
presented in groups as case-series/ IPD not available), 
N° participants (110)
N° studies for which aggregate data were available 
(10)
N° participants (110, 71 ROHHAD, 39 ROHHADNET)
N° studies identiﬁed through database searching 
(318)
N° additional records identiﬁed through other 
sources including contact with researchers (3)
IPD for gender information
N° studies included in analysis (33)
N° participants included in analysis (40)
N° participants excluded (8)
IPD for clinical manifestation
N° studies included in analysis (36)
N° participants included in analysis (48)
N° participants excluded (0)
IPD for tumor presentation
N° studies included in analysis (18)
N° participants included in analysis (19)
N° participants excluded (29)
IPD for laboratory tests 
N° studies included in analysis (28)
N° participants included in analysis (40)
N° participants excluded (8)
IPD for treatment information
N° studies included in analysis (12)
N° participants included in analysis (28)
N° participants excluded (20)
IPD for survival outcome
N° studies included in analysis (36)
N° participants included in analysis (48)
N° participants excluded (0)
Aggregate data for gender information
N° studies included in analysis (4)
N° participants included in analysis (60)
N° participants excluded (50, data not given)
Aggregate data for clinical manifestation
N° studies included in analysis (10)
N° participants included in analysis (110)
N° participants excluded (0)
IPD for tumor presentation
N° studies included in analysis (6)
N° participants included in analysis (39)
N° participants excluded (71)
Aggregate data for laboratory tests 
N° studies included in analysis (4)
N° participants included in analysis (30)
N° participants excluded (80)
Aggregate data for treatment information
N° studies included in analysis (36)
N° participants included in analysis (57)
N° participants excluded (53)
Aggregate data for survival outcome
N° studies included in analysis (10)
N° participants included in analysis (110)







































Figure 1: PRISMA IPD flow diagram.
3.3. Next Generation Sequencing. We described previously
reported human candidate genes [6, 12, 51–54] for
ROHHAD/NET in Table 7. None of these, however, have
been identified in the patient cases to date. In our study, there
were two ROHHADNET patients with available samples for
whole exome sequencing: Case 1, a 15-year-old Korean boy
[7]; and Case 2, a 5-year-old Turkish girl [8]. Details with
regard to these two patients are briefed in Supplementary
Table S2. Currently, there is no known genetic cause for
ROHHAD or ROHHADNET [55]. To identify genetic
variants related to ROHHAD syndrome, we performed
WES for Case 1 and Case 2. Since ROHHAD syndrome in
BioMed Research International 11
Table 3: Clinical presentations of patients with ROHHADNET
syndrome (IPD).
Clinical findings
Total number of patients
(n=48)
Number of patients (%)
Rapid obesity 40 (83.3%)
Hypoventilation 36 (75.0%)
Obstructive sleep apnea 21 (43.8%)
Respiratory distress 5 (10.4%)
Cyanotic episodes 4 (8.3%)
Hypothalamic dysfunction 40 (83.3%)
Growth hormone deficiency 13 (25.3%)
Diabetes insipidus 9 (18.8%)
Polyuria/polydipsia 8 (16.7%)
Central precocious puberty 7 (14.6%)
Hypogonadotropic hypogonadism 2 (4.2%)
Premature thelarche 2 (4.2%)
Autonomic dysregulation 32 (66.7%)
Ophthalmologic abnormality 12 (25.0%)
Altered perception of pain 6 (12.5%)
Gastrointestinal dysmotility 6 (12.5%)
Cold extremity 4 (8.3%)
Neurogenic bladder 4 (8.3%)
Excessive sweating 5 (10.4%)
Thermal dysregulation 3 (6.3%)
Syncope 1 (2.1%)
Urinary incontinence 1 (2.1%)
Behavioral disorders 29 (60.4%)
Irritability & aggression 10 (20.8%)
Fatigue 4 (8.3%)
Social withdrawal 4 (8.3%)
Poor school performance 3 (6.3%)
Intellectual disability 2 (4.2%)
Mood change 2 (4.2%)
Flat affect 2 (4.2%)
Hallucination 2 (4.2%)
Major depressive disorder 1(2.1%)
Attention deficit disorder 1(2.1%)
Psychosis 1(2.1%)
Neurologic abnormality 16 (33.3%)
Seizure 7 (14.6%)
Blurring of consciousness 4 (8.3%)
Sleep disturbance 3 (6.3%)
Developmental delay 3 (6.3%)
Gait disturbance 2 (4.2%)
Nystagmus 1 (2.1%)
General weakness 1 (2.1%)
Table 3: Continued.
Clinical findings
Total number of patients
(n=48)
Number of patients (%)
Other findings
Fever 6 (12.5%)






Megaloblastic anemia 1 (2.1%)
Thrombocytopenia 1 (2.1%)
Acanthosis nigricans 1 (2.1%)
Raynaud phenomenon 1 (2.1%)
Celiac disease 1 (2.1%)
Metabolic alkalosis 1 (2.1%)
Hepatitis C 1 (2.1%)
Buffalo neck 1 (2.1%)
Tonsillar hypertrophy 1 (2.1%)
Abdominal mass 1 (2.1%)
Renal failure 1 (2.1%)
Edema 1 (2.1%)
Pulmonary hypertension 1 (2.1%)
Cough 1 (2.1%)
these individuals was sporadic and had childhood onset,
we assumed the following inheritance patterns: (1) biallelic
variants in recessive genes and (2) hemizygous variants in
X-chromosome genes in Case 1. Variant filtering reduced the
number of candidate genes to five in Case 1 and three in Case
2, respectively, as outlined in Supplementary Table S3. In
Case 1, variant filtering was begun with 188,415 variants from
the normal reference sequence. This number was reduced
to 1,914 upon exclusion of homozygous and hemizygous
variants in healthy domestic individuals, common variants
(minor allele frequencies >1% in public databases), and
synonymous variants. Upon considering only those genes
with hemizygous variants or more than two variants in the
same gene, the number of variants was further reduced to 50
variants (14 genes). Exclusion of artefacts by direct inspection
of sequence alignment and exclusion of variants with minor
allele frequencies < 0.005 in public databases left six variants
in three candidate genes—PIK3R3, SPTBN5, and PCF11
(Supplementary Table S4). These variants were predicted
likelihood to be deleterious for the function of the encoded
protein in some prediction tools and PIK3R3, SPTBN5, and
PCF11 are not linked to any disease phenotype in human
yet. The WES of Case 2 was analyzed in the same manner to
identify candidate variants (Supplementary Table S4), but
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Table 4: Laboratory findings of patients with ROHHADNET
syndrome (IPD).
Laboratory findings Total number of patients (n=48)






















No information 31/48 (64.6%)
ABGA: Arterial blood gas analysis, IGF-1: Insulin-like growth factor-1.
†Hypoxemia is defined in terms of reduced partial pressure of oxygen below
80 mmHg or decreased oxygen saturation less than 90%.
‡Hypercapnia is defined in termsof elevated carbondioxide above 45mmHg.
none of them overlapped with variants identified in Case 1;
SRMS and ZNF4 were not linked to any disease phenotypes,
whereas mutations in KMT2B, which encodes lysine-specific
methyltransferase 2B, cause childhood-onset dystonia [56].
All variants were confirmed by Sanger sequencing of the
DNA of the affected individuals.
In addition, we analyzed CNVs; has been previously
abbreviated using WES in Case 1 and Case 2. The CNVs
detected by both EXCAVATOR and ExomeDepth tools were
38 in Case 1 and 48 in Case 2, respectively. We specifically
focused on deletion or duplication of alleles in an AR
pattern; however, there was no surviving CNV upon manual
inspection of WES data.
4. Discussion
ROHHAD/NET is a rare disease and differential diagnosis
from other obesity syndromes or neuroendocrine disorders
requires clinical suspicion based on its phenotype. The
genetic basis of this syndrome is still unknown.
The first part of this study is a systematic review on
phenotypes of ROHHAD/NET involving 46 studies with 158
patients. Clinical manifestation, laboratory findings, tumor
characteristics, and patient courses were reviewed.The results
Table 5: Treatment of case-reported patients with ROHHADNET
syndrome (IPD).
Treatment Total number of patients (n = 48)
Number of patients (%)
Respiratory support 21 (43.8%)
Mechanical ventilation 20 (41.7%)
BIPAP 7 (14.6%)
CPAP 1 (2.1%)




Steroid pulse therapy 2 (4.2%)
Prednisolone 2 (2.1%)
Dexamethasone 1 (2.1%)
Fluid resuscitation 4 (8.3%)
Intravenous immunoglobulins 7 (14.6%)





Desmopressin acetate 2 (4.2%)




Hypertensive medication 1 (2.1%)
Procedure 2 (4.2%)
Brain hypothermia 1 (2.1%)
Tonsillectomy 1 (2.1%)
BIPAP: bilevel positive airway pressure; CPAP: Continuous Positive Airway
Pressure; GH: growth hormone.
showed that it has a pediatric onset and it is noteworthy
that no adult case has been reported to date. There was a
female preponderance, with the girls being twice as often
affected than the boys, consistently in both IPD and APD.
This finding is in contrast to what has been reported on
acquired sleep disorders with a 2:1 predominance of males
in the reported frequency of obstructive sleep apnea [57].
Rapid obesity may often be the first recognizable sign,
since other endocrine dysfunctions are gradually present.
The results implicated that common endocrine disorders
such as hypothyroidism or precocious puberty may be early
signs for recognition. In addition, it has been reported that
one of the major effects of hypothyroidism is its influence
on the central ventilatory control and that both hypoxic
and hypercapnic ventilatory impairment are significantly
present in untreated thyroid insufficiency [58]. Such impaired
ventilatory responses are thought to be related to the decrease
in oxygen consumption associated with hypothyroidism [59].
In that, it is tempting to speculate that disturbance of thyroid
function may be in part responsible for respiratory distress
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in patients with ROHHADNET. Electrolyte imbalance, espe-
cially dysnatremia, was present in a majority of the patients,
requiring attention. Impaired water balancing condition such
as polydipsia or diabetes insipidus due to hypothalamic
dysfunctionmayhave caused dysnatremia. Ganglioneuromas
were the most common type of accompanied tumor and
may presented not only as abdominal but also as mediastinal
masses. We therefore suggest that suspected patients take
both thoracic and abdominal imaging to screen for tumors.
As ROHHAD/NET involves progressive impairment of the
respiratory center, we observed that artificial ventilation
was commonly initiated from the first place. Cardiac arrest
probably due to preceding respiratory arrest was the major
cause of deaths in these patients. We noted that all of the
patients were already exposed to hypoxemia at the time of
diagnosis. We believe that earlier recognition and timely
application of pressure supporting devices during sleep may
improve the quality of life and prevent sudden death.
The second part of this study was aWESwhich attempted
to identify the genetic basis of ROHHAD/NET. It has been
noted that central hypoventilation syndrome (CHS) result-
ing from PHOX2B mutations is associated with tumors of
neural crest origin (neuroblastoma, ganglioneuroblastoma,
and ganglioneuroma) in approximately 6% of cases [59].
However, the association of ROHHADNET and PHOX2B
mutations has not been identified. Recently, several stud-
ies have made progress in investigating genetic basis of
ROHHAD/NET (Table 7). Thaker et al.[12] identified a de
novo retinoic acid-induced 1 (RAI1) gene mutation in a child
with ROHHAD and proposed RAI1 as a candidate gene
for children with morbid obesity. Furthermore, there were
studies which performed NGS in a set of ROHHAD/NET
patients [6, 51, 52, 54]. Rand and colleagues [54] analyzed 5-
hydroxytryptamine receptor 1A (HTR1A), orthopedia (OTP),
and Adenylate Cyclase Activating Polypeptide 1 (ADCYAP1,
formerly PACAP) genes which are involved in the embry-
ologic development of the hypothalamus and autonomic
nervous system in a set of 25 ROHHAD patients and 25
matched controls. Although therewere no significantly corre-
lating variations, this report provided evidence that variation
of the HTR1A, OTP, and ADCYAP1 genes are unlikely
responsible for ROHHAD/NET. Barclay et al. [51] analyzed 16
ROHHAD patients using a combination of NGS and Sanger
sequencing. They examined mutations in the exons of the
genes for hypocretin and accompanying receptors, namely,
HCRT, HCRTR1, and HCRTR2, and found no rare or novel
mutations. In this study, we also identified rare variants in
two ROHHAD/NET patients. However, the causality of these
variants remains unclear and demands further investigation.
Nevertheless, we believe that accumulation of these attempts
would contribute to progress.
There are some limitations in our research. Firstly, we
could not analyze the relationship between the treatments
and the subsequent outcomes. Secondly, there remains the
possibility of existing case reports or series that were not
accessible.Thirdly, some studies only had grouped datawhere
IPD were not available. Nevertheless, this study also has its
strengths in that it provides a pooled data and combined
evidence on a disease of extreme rarity.
ROHHAD/NET is a rare disease, which has pediatric
onset and female preponderance. Rapid obesity and hypotha-
lamic dysfunction are earliest detectable signs. Prompt recog-
nition and timely application of respiratory support may
prevent grave complications leading to unprepared mortality.
WES on 2 ROHHADNET patients identified no significant
mutations or copy number variations. Further analyses of
patients in prospective studies are required.
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